Distinct clinical outcomes of non-small cell lung cancer patients with Epidermal Growth Factor Receptor (EGFR) mutations treated with EGFR tyrosine kinase inhibitors: Non-responders versus responders

Shih Hsin Hsiao, H. Eugene Liu, Hsin Lun Lee, Chii Lan Lin, Wei Yu Chen, Zhung Han Wu, Sey En Lin, Ling Ling Chiang, Chi Li Chung

研究成果: 雜誌貢獻文章

8 引文 (Scopus)

摘要

Introduction: Treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has been associated with favorable progression free survival (PFS) in patients with non-small cell lung cancers (NSCLC) harboring EGFR mutations. However, a subset of this population doesn't respond to EGFR-TKI treatment. Therefore, the present study aimed to elucidate survival outcome in NSCLC EGFR-mutant patients who were treated with EGFR TKIs. Methods: Among the 580 consecutive NSCLC patients who were treated at our facility between 2008 and 2012, a total of 124 treatment-naïve, advanced NSCLC, EGFR-mutant patients treated with EGFR TKIs were identified and grouped into nonresponders and responders for analyses. Results: Of 124 patients, 104 (84%) responded to treatment, and 20 (16%) did not; and the overall median PFS was 9.0 months. Notably, the PFS, overall survival (OS) and survival rates were significantly unfavorable in non-responders (1.8 vs. 10.3 months, hazard ratio (HR) = 29.2, 95% confidence interval (CI), 13.48-63.26, P
原文英語
文章編號e83266
期刊PLoS One
8
發行號12
DOIs
出版狀態已發佈 - 十二月 23 2013

指紋

lung neoplasms
Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
tyrosine
phosphotransferases (kinases)
Cells
mutation
Mutation
Disease-Free Survival
cells
mutants
Survival
Therapeutics
epidermal growth factor receptors
confidence interval
Hazards
Survival Rate
survival rate
Confidence Intervals

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

引用此文

@article{960cd87a965e4456b5e3297caa2711a2,
title = "Distinct clinical outcomes of non-small cell lung cancer patients with Epidermal Growth Factor Receptor (EGFR) mutations treated with EGFR tyrosine kinase inhibitors: Non-responders versus responders",
abstract = "Introduction: Treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has been associated with favorable progression free survival (PFS) in patients with non-small cell lung cancers (NSCLC) harboring EGFR mutations. However, a subset of this population doesn't respond to EGFR-TKI treatment. Therefore, the present study aimed to elucidate survival outcome in NSCLC EGFR-mutant patients who were treated with EGFR TKIs. Methods: Among the 580 consecutive NSCLC patients who were treated at our facility between 2008 and 2012, a total of 124 treatment-na{\"i}ve, advanced NSCLC, EGFR-mutant patients treated with EGFR TKIs were identified and grouped into nonresponders and responders for analyses. Results: Of 124 patients, 104 (84{\%}) responded to treatment, and 20 (16{\%}) did not; and the overall median PFS was 9.0 months. Notably, the PFS, overall survival (OS) and survival rates were significantly unfavorable in non-responders (1.8 vs. 10.3 months, hazard ratio (HR) = 29.2, 95{\%} confidence interval (CI), 13.48-63.26, P",
author = "Hsiao, {Shih Hsin} and Liu, {H. Eugene} and Lee, {Hsin Lun} and Lin, {Chii Lan} and Chen, {Wei Yu} and Wu, {Zhung Han} and Lin, {Sey En} and Chiang, {Ling Ling} and Chung, {Chi Li}",
year = "2013",
month = "12",
day = "23",
doi = "10.1371/journal.pone.0083266",
language = "English",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "12",

}

TY - JOUR

T1 - Distinct clinical outcomes of non-small cell lung cancer patients with Epidermal Growth Factor Receptor (EGFR) mutations treated with EGFR tyrosine kinase inhibitors

T2 - Non-responders versus responders

AU - Hsiao, Shih Hsin

AU - Liu, H. Eugene

AU - Lee, Hsin Lun

AU - Lin, Chii Lan

AU - Chen, Wei Yu

AU - Wu, Zhung Han

AU - Lin, Sey En

AU - Chiang, Ling Ling

AU - Chung, Chi Li

PY - 2013/12/23

Y1 - 2013/12/23

N2 - Introduction: Treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has been associated with favorable progression free survival (PFS) in patients with non-small cell lung cancers (NSCLC) harboring EGFR mutations. However, a subset of this population doesn't respond to EGFR-TKI treatment. Therefore, the present study aimed to elucidate survival outcome in NSCLC EGFR-mutant patients who were treated with EGFR TKIs. Methods: Among the 580 consecutive NSCLC patients who were treated at our facility between 2008 and 2012, a total of 124 treatment-naïve, advanced NSCLC, EGFR-mutant patients treated with EGFR TKIs were identified and grouped into nonresponders and responders for analyses. Results: Of 124 patients, 104 (84%) responded to treatment, and 20 (16%) did not; and the overall median PFS was 9.0 months. Notably, the PFS, overall survival (OS) and survival rates were significantly unfavorable in non-responders (1.8 vs. 10.3 months, hazard ratio (HR) = 29.2, 95% confidence interval (CI), 13.48-63.26, P

AB - Introduction: Treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has been associated with favorable progression free survival (PFS) in patients with non-small cell lung cancers (NSCLC) harboring EGFR mutations. However, a subset of this population doesn't respond to EGFR-TKI treatment. Therefore, the present study aimed to elucidate survival outcome in NSCLC EGFR-mutant patients who were treated with EGFR TKIs. Methods: Among the 580 consecutive NSCLC patients who were treated at our facility between 2008 and 2012, a total of 124 treatment-naïve, advanced NSCLC, EGFR-mutant patients treated with EGFR TKIs were identified and grouped into nonresponders and responders for analyses. Results: Of 124 patients, 104 (84%) responded to treatment, and 20 (16%) did not; and the overall median PFS was 9.0 months. Notably, the PFS, overall survival (OS) and survival rates were significantly unfavorable in non-responders (1.8 vs. 10.3 months, hazard ratio (HR) = 29.2, 95% confidence interval (CI), 13.48-63.26, P

UR - http://www.scopus.com/inward/record.url?scp=84893498040&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893498040&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0083266

DO - 10.1371/journal.pone.0083266

M3 - Article

C2 - 24376677

AN - SCOPUS:84893498040

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 12

M1 - e83266

ER -